CAYMAN CHEMICAL COMPANY Non-Antibody Products — page 808 of 865
Non-Antibody Products
Page 808 of 865
| Name | Description | Size | Catalog # | |
|---|---|---|---|---|
| TNFRSF7/CD27 Extracellular Domain (human, recombinant) | Source: Active recombinant C-terminal human IgG1 Fc-His-tagged CD27 expres… | 1 mg | 31828-1 | More Info |
| TNFRSF7/CD27 Extracellular Domain (human, recombinant) | Source: Active recombinant C-terminal human IgG1 Fc-His-tagged CD27 expres… | 100 µg | 31828-100 | More Info |
| TNFRSF8/CD30 Long Isoform Extracellular Domain (human, recombinant) | Source: Active recombinant C-terminal human IgG1 Fc-His-tagged CD30 expres… | 1 mg | 31829-1 | More Info |
| TNFRSF8/CD30 Long Isoform Extracellular Domain (human, recombinant) | Source: Active recombinant C-terminal human IgG1 Fc-His-tagged CD30 expres… | 100 µg | 31829-100 | More Info |
| TNFSF8/CD30 Ligand Extracellular Domain (human, recombinant) | Source: Active recombinant N-terminal human IgG1 Fc-tagged CD30L expressed… | 1 mg | 40213-1 | More Info |
| TNFSF8/CD30 Ligand Extracellular Domain (human, recombinant) | Source: Active recombinant N-terminal human IgG1 Fc-tagged CD30L expressed… | 200 µg | 40213-200 | More Info |
| TNFSF4 Extracellular Domain (human, recombinant) | Source: Active recombinant N-terminal mouse IgG1 Fc-tagged human TNFSF4 ex… | 1 mg | 32065-1 | More Info |
| TNFSF4 Extracellular Domain (human, recombinant) | Source: Active recombinant N-terminal mouse IgG1 Fc-tagged human TNFSF4 ex… | 100 µg | 32065-100 | More Info |
| TNO155 | A SHP-2 inhibitor (IC50 = 0.011 µM); selective for SHP-2 over a pane… | 1 mg | 32525-1 | More Info |
| TNO155 | A SHP-2 inhibitor (IC50 = 0.011 µM); selective for SHP-2 over a pane… | 5 mg | 32525-5 | More Info |
| TNP | An IP6K (IC50 = 0.55 µM; Ki = 0.24 µM) and IP3K (IC50 = 10.2 &… | 1 mg | 21189-1 | More Info |
| TNP | An IP6K (IC50 = 0.55 µM; Ki = 0.24 µM) and IP3K (IC50 = 10.2 &… | 10 mg | 21189-10 | More Info |
| TNP | An IP6K (IC50 = 0.55 µM; Ki = 0.24 µM) and IP3K (IC50 = 10.2 &… | 5 mg | 21189-5 | More Info |
| TNP | An IP6K (IC50 = 0.55 µM; Ki = 0.24 µM) and IP3K (IC50 = 10.2 &… | 50 mg | 21189-50 | More Info |
| TNP-470 | A synthetic analog of fumagillin that inhibits angiogenesis; irreversibly… | 10 mg | 16449-10 | More Info |
| TNP-470 | A synthetic analog of fumagillin that inhibits angiogenesis; irreversibly… | 25 mg | 16449-25 | More Info |
| TNP-470 | A synthetic analog of fumagillin that inhibits angiogenesis; irreversibly… | 5 mg | 16449-5 | More Info |
| TNP-ATP (sodium salt) | A derivative of ATP and an antagonist of the purinergic P2Y1, P2X3, and P2… | 3.6 mg | 38492-36 | More Info |
| TNP-ATP (triethylammonium salt) | An antagonist of P2X receptors and a fluorescent probe; an antagonist at t… | 5 mg | 20902-5 | More Info |
| TNP-β-L-GTP (sodium salt) | An enantiomer of TNP-GTP | 700 µg | 38830-700 | More Info |
| TNP-GTP (sodium salt) | A fluorescent derivative of GTP; an antagonist of the purinergic P2X2 and… | 700 µg | 38570-700 | More Info |
| TNT-b10 | A lipidoid; has been used in the formation of LLNs; LLNs containing TNT-b1… | 1 mg | 39294-1 | More Info |
| TNT-b10 | A lipidoid; has been used in the formation of LLNs; LLNs containing TNT-b1… | 10 mg | 39294-10 | More Info |
| TNT-b10 | A lipidoid; has been used in the formation of LLNs; LLNs containing TNT-b1… | 5 mg | 39294-5 | More Info |
| Tobramycin | An aminoglycoside antibiotic; binds to the 30S ribosomal subunit, inhibiti… | 100 mg | 14596-100 | More Info |
| Tobramycin | An aminoglycoside antibiotic; binds to the 30S ribosomal subunit, inhibiti… | 50 mg | 14596-50 | More Info |
| Tobramycin | An aminoglycoside antibiotic; binds to the 30S ribosomal subunit, inhibiti… | 500 mg | 14596-500 | More Info |
| Toceranib | A small molecule, multi-targeted receptor tyrosine kinase inhibitor; block… | 1 mg | 17714-1 | More Info |
| Toceranib | A small molecule, multi-targeted receptor tyrosine kinase inhibitor; block… | 10 mg | 17714-10 | More Info |
| Toceranib | A small molecule, multi-targeted receptor tyrosine kinase inhibitor; block… | 5 mg | 17714-5 | More Info |
| Toceranib | A small molecule, multi-targeted receptor tyrosine kinase inhibitor; block… | 50 mg | 17714-50 | More Info |
| Tocofersolan | A nonionic surfactant; CMC = 0.02 mM at room temperature; inhibits P-gp su… | 1 g | 34661-1 | More Info |
| Tocofersolan | A nonionic surfactant; CMC = 0.02 mM at room temperature; inhibits P-gp su… | 10 g | 34661-10 | More Info |
| Tocofersolan | A nonionic surfactant; CMC = 0.02 mM at room temperature; inhibits P-gp su… | 25 g | 34661-25 | More Info |
| Tocofersolan | A nonionic surfactant; CMC = 0.02 mM at room temperature; inhibits P-gp su… | 5 g | 34661-5 | More Info |
| Todralazine (hydrochloride) | A β2-adrenergic receptor antagonist with peripheral vasodilator activ… | 1 g | 20893-1 | More Info |
| Todralazine (hydrochloride) | A β2-adrenergic receptor antagonist with peripheral vasodilator activ… | 250 mg | 20893-250 | More Info |
| Todralazine (hydrochloride) | A β2-adrenergic receptor antagonist with peripheral vasodilator activ… | 500 mg | 20893-500 | More Info |
| TOFA | A non-cytotoxic inhibitor of ACC and fatty acid synthesis; blocks the inco… | 10 mg | 10005263-10 | More Info |
| TOFA | A non-cytotoxic inhibitor of ACC and fatty acid synthesis; blocks the inco… | 100 mg | 10005263-100 | More Info |
| TOFA | A non-cytotoxic inhibitor of ACC and fatty acid synthesis; blocks the inco… | 5 mg | 10005263-5 | More Info |
| TOFA | A non-cytotoxic inhibitor of ACC and fatty acid synthesis; blocks the inco… | 50 mg | 10005263-50 | More Info |
| Tofacitinib (citrate) | A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respe… | 10 mg | 11598-10 | More Info |
| Tofacitinib (citrate) | A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respe… | 25 mg | 11598-25 | More Info |
| Tofacitinib (citrate) | A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respe… | 5 mg | 11598-5 | More Info |
| Tofacitinib (citrate) | A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respe… | 50 mg | 11598-50 | More Info |
| Tofacitinib-d3 (citrate) | An internal standard for the quantification of tofacitinib by GC- or LC-MS | 1 mg | 25046-1 | More Info |
| Tofisopam | An analytical reference standard categorized as a benzodiazepine; intended… | 1 mg | 22026-1 | More Info |
| Tofisopam | An analytical reference standard categorized as a benzodiazepine; intended… | 5 mg | 22026-5 | More Info |
| Tofogliflozin (hydrate) | A potent inhibitor of SGLT2 (Kis = 2.9, 14.9, and 6.4 nM for human, rat, a… | 1 mg | 23509-1 | More Info |
| Tofogliflozin (hydrate) | A potent inhibitor of SGLT2 (Kis = 2.9, 14.9, and 6.4 nM for human, rat, a… | 10 mg | 23509-10 | More Info |
| Tofogliflozin (hydrate) | A potent inhibitor of SGLT2 (Kis = 2.9, 14.9, and 6.4 nM for human, rat, a… | 25 mg | 23509-25 | More Info |
| Tofogliflozin (hydrate) | A potent inhibitor of SGLT2 (Kis = 2.9, 14.9, and 6.4 nM for human, rat, a… | 5 mg | 23509-5 | More Info |
| Tolazamide | A sulfonylurea inhibitor of SUR1 / KIR6.2 (IC50 = 4.2 µM); enhances… | 10 mg | 23545-10 | More Info |
| Tolazamide | A sulfonylurea inhibitor of SUR1 / KIR6.2 (IC50 = 4.2 µM); enhances… | 25 mg | 23545-25 | More Info |
| Tolazamide | A sulfonylurea inhibitor of SUR1 / KIR6.2 (IC50 = 4.2 µM); enhances… | 5 mg | 23545-5 | More Info |
| Tolazamide | A sulfonylurea inhibitor of SUR1 / KIR6.2 (IC50 = 4.2 µM); enhances… | 50 mg | 23545-50 | More Info |
| Tolazoline (hydrochloride) | An α1-AR (IC50 = 3,200 nM) and α2-AR antagonist (Kis = 112, 1,… | 10 g | 18865-10 | More Info |
| Tolazoline (hydrochloride) | An α1-AR (IC50 = 3,200 nM) and α2-AR antagonist (Kis = 112, 1,… | 25 g | 18865-25 | More Info |
| Tolazoline (hydrochloride) | An α1-AR (IC50 = 3,200 nM) and α2-AR antagonist (Kis = 112, 1,… | 5 g | 18865-5 | More Info |
| Tolbutamide | A SUR1 / Kir6.2 channel inhibitor (IC50 = 4.9 µM); selective for SUR… | 100 mg | 19888-100 | More Info |
| Tolbutamide | A SUR1 / Kir6.2 channel inhibitor (IC50 = 4.9 µM); selective for SUR… | 25 mg | 19888-25 | More Info |
| Tolbutamide | A SUR1 / Kir6.2 channel inhibitor (IC50 = 4.9 µM); selective for SUR… | 250 mg | 19888-250 | More Info |
| Tolbutamide | A SUR1 / Kir6.2 channel inhibitor (IC50 = 4.9 µM); selective for SUR… | 50 mg | 19888-50 | More Info |
| Tolbutamide-d9 | An internal standard for the quantification of tolbutamide by GC- or LC-MS | 1 mg | 30738-1 | More Info |
| Tolbutamide-d9 | An internal standard for the quantification of tolbutamide by GC- or LC-MS | 10 mg | 30738-10 | More Info |
| Tolbutamide-d9 | An internal standard for the quantification of tolbutamide by GC- or LC-MS | 5 mg | 30738-5 | More Info |
| Tolcapone | A reversible inhibitor of COMT (Ki = 0.27 nM for human recombinant COMT);… | 10 mg | 20768-10 | More Info |
| Tolcapone | A reversible inhibitor of COMT (Ki = 0.27 nM for human recombinant COMT);… | 100 mg | 20768-100 | More Info |
| Tolcapone | A reversible inhibitor of COMT (Ki = 0.27 nM for human recombinant COMT);… | 5 mg | 20768-5 | More Info |
| Tolcapone | A reversible inhibitor of COMT (Ki = 0.27 nM for human recombinant COMT);… | 50 mg | 20768-50 | More Info |
| Tolcapone-d4 | An internal standard for the quantification of tolcapone by GC- or LC-MS,, | 1 mg | 28697-1 | More Info |
| Tolebrutinib | An irreversible inhibitor of BTK (IC50 = 1 nM); decreases the number of CD… | 10 mg | 37723-10 | More Info |
| Tolebrutinib | An irreversible inhibitor of BTK (IC50 = 1 nM); decreases the number of CD… | 5 mg | 37723-5 | More Info |
| Tolfenamic Acid | An NSAID with anticancer activity; selective for COX-2 over COX-1 in canin… | 10000 mg | 70480-10 | More Info |
CAYMAN CHEMICAL COMPANY
CAYMAN CHEMICAL COMPANY
1180 East Ellsworth Road
Ann Arbor MI 48108
P: (734) 971-3335
P: (800) 364-9897 (USA & Canada only)
F: (734) 971-3640
Customer Service: custserv@caymanchem.com
Technical Support: techserv@caymanchem.com
Sales: sales@caymanchem.com
http://www.caymanchem.com
Return to Profile